Compare Fresenius Kabi Onco. with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs TTK HEALTHCARE - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. TTK HEALTHCARE FRESENIUS KABI ONCO./
TTK HEALTHCARE
 
P/E (TTM) x 22.1 18.8 118.0% View Chart
P/BV x 3.1 1.5 207.3% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 FRESENIUS KABI ONCO.   TTK HEALTHCARE
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
TTK HEALTHCARE
Mar-19
FRESENIUS KABI ONCO./
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1761,215 14.5%   
Low Rs79610 12.9%   
Sales per share (Unadj.) Rs37.7444.4 8.5%  
Earnings per share (Unadj.) Rs5.117.2 29.5%  
Cash flow per share (Unadj.) Rs6.727.6 24.3%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs42.5177.9 23.9%  
Shares outstanding (eoy) m158.2314.13 1,119.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.1 164.4%   
Avg P/E ratio x25.052.9 47.2%  
P/CF ratio (eoy) x18.933.0 57.3%  
Price / Book Value ratio x3.05.1 58.3%  
Dividend payout %029.0 0.0%   
Avg Mkt Cap Rs m20,13512,894 156.2%   
No. of employees `0001.22.3 49.8%   
Total wages/salary Rs m7031,307 53.8%   
Avg. sales/employee Rs Th5,176.22,715.7 190.6%   
Avg. wages/employee Rs Th610.4565.3 108.0%   
Avg. net profit/employee Rs Th699.6105.4 663.7%   
INCOME DATA
Net Sales Rs m5,9636,279 95.0%  
Other income Rs m1878 23.2%   
Total revenues Rs m5,9816,356 94.1%   
Gross profit Rs m1,430496 288.6%  
Depreciation Rs m258147 175.8%   
Interest Rs m-2634 -76.9%   
Profit before tax Rs m1,216393 309.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342149 229.8%   
Profit after tax Rs m806244 330.7%  
Gross profit margin %24.07.9 303.8%  
Effective tax rate %28.137.9 74.2%   
Net profit margin %13.53.9 348.2%  
BALANCE SHEET DATA
Current assets Rs m5,1022,717 187.8%   
Current liabilities Rs m2,3851,571 151.9%   
Net working cap to sales %45.618.3 249.5%  
Current ratio x2.11.7 123.6%  
Inventory Days Days15032 466.6%  
Debtors Days Days11347 242.8%  
Net fixed assets Rs m5,148991 519.5%   
Share capital Rs m158141 112.0%   
"Free" reserves Rs m6,5562,373 276.3%   
Net worth Rs m6,7322,514 267.7%   
Long term debt Rs m9523 28,005.9%   
Total assets Rs m10,3884,158 249.8%  
Interest coverage x-45.812.6 -362.9%   
Debt to equity ratio x0.10 10,460.1%  
Sales to assets ratio x0.61.5 38.0%   
Return on assets %7.56.7 112.5%  
Return on equity %12.09.7 123.5%  
Return on capital %14.616.9 86.2%  
Exports to sales %74.53.6 2,076.3%   
Imports to sales %24.80.5 5,026.3%   
Exports (fob) Rs m4,441225 1,971.8%   
Imports (cif) Rs m1,47731 4,773.5%   
Fx inflow Rs m5,298225 2,352.4%   
Fx outflow Rs m1,77271 2,492.2%   
Net fx Rs m3,525154 2,287.9%   
CASH FLOW
From Operations Rs m1,274173 736.0%  
From Investments Rs m-1,20497 -1,247.9%  
From Financial Activity Rs m-196-307 63.8%  
Net Cashflow Rs m-126-38 335.0%  

Share Holding

Indian Promoters % 0.0 65.4 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 3.7 8.1%  
FIIs % 9.6 5.2 184.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 25.8 35.3%  
Shareholders   42,599 12,723 334.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 60.1% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, TTK HEALTHCARE has posted a net profit of Rs 49 m (down 60.1% YoY). Sales on the other hand came in at Rs 1 bn (up 2.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS